tesamorelin + CJC-1295 + ipamorelin

a three-peptide GH-axis blend with no located direct study, whose CJC variant, component forms, and ratio must be known before even its duration can be described.

tier F · growth hormone · 0 located fixed-blend studies

verdict

three characterized component mechanisms do not create a characterized product. until the CJC variant, tesamorelin formulation, ipamorelin form, and per-vial ratio are verified, the blend's PK and outcome claims stay blocked.

if you're asking whether the three-way blend has been studied — no fixed-dose animal or human study of tesamorelin, CJC-1295, and ipamorelin together was located. every pharmacokinetic and safety statement comes from one component at a time.

if you're asking why the CJC variant matters — true CJC-1295 with DAC carries an albumin-reactive group and formed an albumin conjugate in rat work; the DAC molecule had a measured human half-life of 5.8 to 8.1 days. Modified GRF(1-29), widely marketed as CJC-1295 no-DAC, lacks that group and cannot inherit the multi-day value. FDA notes that no direct DAC-versus-no-DAC half-life comparison establishes how much of the difference is caused by DAC itself. the names are not interchangeable.

if you're asking for the blend's half-life — it is not assignable while formulation is unresolved. if DAC is confirmed, a 167-hour midpoint can describe the longest characterized component only, never a measured blend curve. if no-DAC is confirmed, that number is invalid and the longest directly characterized component is ipamorelin at about two hours after human intravenous administration.

if you're asking whether tesamorelin's approval makes the blend safe or approved — no. tesamorelin is approved alone for reducing excess abdominal fat in adults with HIV and lipodystrophy. that label does not cover CJC-1295, ipamorelin, a three-way blend, or general body-composition use.

component studies are labeled as component-only. no combined dose, protocol, or human-equivalent dose is synthesized.

why F-tier

F-tier applies while formulation identity is unresolved and no fixed-blend safety study is located. The same CJC label can refer to molecules whose duration differs by orders of magnitude, tesamorelin's approval does not transfer to a combination, and no located animal or human study tests all three together. Exact verified forms and ratios could support a molecule-level reassessment, but they would not create a clinical outcome or safety record for the blend.

the core tension

The component mechanisms and some component PK are measurable, but the product is not. An unresolved CJC label can hide either a multi-day DAC molecule with an albumin-reactive group or a short no-DAC analog, while adding a second GHRH agonist and ipamorelin creates a safety and exposure question no located fixed-blend study has answered.

what it is

A proposed fixed mixture of tesamorelin, a 44-amino-acid GHRH analog; CJC-1295, which must be identified as with DAC or no-DAC; and ipamorelin, a five-residue ghrelin-receptor agonist. The exact tesamorelin formulation, CJC variant, ipamorelin salt or free base, and per-vial amount of each component define the product.

what it does

Tesamorelin and CJC both stimulate the pituitary GHRH receptor. Ipamorelin stimulates GHS-R1a, the ghrelin receptor, on the GH-release pathway. Those component mechanisms can converge on growth-hormone release and downstream IGF-1. No study quantifies what happens when all three are co-formulated or establishes that two GHRH agonists add benefit rather than prolonged or excessive pathway exposure.

origin

The three components came from separate development programs. Tesamorelin became an FDA-approved single-ingredient drug for a narrow HIV-associated indication. CJC-1295 with DAC reached early human pharmacology studies. Ipamorelin reached human PK and an unsuccessful postoperative-ileus program. The three-way vial is a market formulation, not a product developed or tested by those programs.

why researchers are interested

The sales logic is maximal pathway coverage: two GHRH-side signals plus a ghrelin-receptor signal. The evidence logic is weaker. Component mechanisms can explain why GH and IGF-1 might rise, but they cannot specify the finished product's curve, interaction size, benefit, or safety without exact identity and a combination study.

does it work

The individual receptors and component PK are real. No direct fixed-product outcome study was located. F-tier applies while identity is unresolved because the CJC ambiguity alone can change the governing duration from hours to days, and because component approval and component PK do not transfer to an unstudied combination.

claims vs the data

• the blend combines three complementary GH pathways — partially true — ipamorelin supplies a ghrelin-receptor signal, but tesamorelin and CJC both act on the GHRH receptor. whether two GHRH agonists add useful benefit or only exposure is untested.
• CJC-1295 gives the blend a one-week half-life — unsupported unless DAC is verified — 5.8 to 8.1 days belongs to CJC-1295 with DAC in a component study. no-DAC products and unresolved labels cannot inherit it, and the blend itself was not measured.
• tesamorelin makes the blend FDA approved — contradicted — the approval is for single-ingredient tesamorelin in a narrow HIV-associated indication. neither the added components nor the combination is approved.
• component doses can be added to create a blend protocol — contradicted — different products, routes, populations, and formulations cannot be merged into a validated fixed-dose regimen. no combined schedule is published here.
• the three-way blend has established safety — unsupported — no fixed-blend toxicology or clinical safety study was located. component warnings and formulation-quality risks remain, while interaction magnitude is unknown.

key facts

• molecular formula: not one formula; depends on exact component forms and salts
• molecular weight: tesamorelin about 5136 Da; CJC-1295 with DAC free base 3647.95 Da; ipamorelin about 711.9 Da
• amino acids: 44 + 30 if CJC-1295 with DAC + 5; no-DAC identity must be stated separately
• half-life: blend unknown; 5.8 to 8.1 days belongs only to confirmed CJC-1295 with DAC
• type: identity-gated GHRH analog + GHRH analog + GHS-R1a agonist blend
• CAS: 901758-09-6 / CJC variant required / 170851-70-4
• 0 located fixed-blend animal or human studies
• 2 GHRH-receptor agonist components
• 5.8-8.1 d confirmed CJC-1295 DAC component only
• 4 identity fields required before PK

frequently asked questions

What is tesamorelin + CJC-1295 + ipamorelin blend?

It is a market-described mixture of two GHRH-receptor agonists, tesamorelin and CJC-1295, plus the ghrelin-receptor agonist ipamorelin. No fixed three-way study was located, and the exact component forms and ratio define what the product is.

Does it matter whether CJC-1295 has DAC?

Yes. CJC-1295 with DAC carries an albumin-reactive group, formed an albumin conjugate in rat work, and has multi-day human PK. Modified GRF(1-29), often sold as CJC-1295 no-DAC, lacks the DAC group and cannot inherit that measured DAC-component duration.

What is the half-life of the triple blend?

Unknown and formulation-blocked. No blend PK study exists. A multi-day value can describe only a confirmed DAC component, while an unresolved or no-DAC product cannot use it.

Has the exact blend been tested in people?

No fixed-dose human study of all three components together was located. Human evidence belongs to individual components and different indications or routes.

Is the blend safe?

Its safety is uncharacterized. Component risks include GH and IGF-1 elevation, glucose intolerance, fluid retention, hypersensitivity, immunogenicity, injection-site injury, and product-quality risks. Combination magnitude and long-term risk are unknown.

Is the blend FDA approved?

No fixed blend is FDA approved. Tesamorelin alone is approved for excess abdominal fat in adults with HIV and lipodystrophy. No approval was located for CJC-1295, ipamorelin, or the fixed three-way blend in the regulator records reviewed, and tesamorelin's label does not transfer to them.

related peptides

• tesamorelin — FDA-approved single-ingredient GHRH analog
• cjc-1295 — DAC identity and multi-day component PK
• ipamorelin — ghrelin-receptor component with human IV PK
• cjc+ipa blend — two-component precedent that also requires a CJC identity

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.